Pacific Biosciences of California, Inc. (PACB) is a publicly traded Healthcare sector company. As of May 21, 2026, PACB trades at $1.21 with a market cap of $357.19M and a P/E ratio of -2.71. PACB moved +3.91% today. Year to date, PACB is -39.90%; over the trailing twelve months it is +16.67%. Its 52-week range spans $0.85 to $2.73. Analyst consensus is neutral with an average price target of $2.38. Rallies surfaces PACB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes PACB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $1.21 |
| Market Cap | $357.19M |
| P/E Ratio | -2.71 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.73 |
| 52-Week Low | $0.85 |
| Volume | 14.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $160.03M |
| Net Income | $-128.58M |
| Gross Margin | 37.49% |
4 analysts cover PACB: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.38.